CYDY News and Press, CytoDyn Inc From 10/10/23

North Dallas Bank & Trust Co. (NODB) is expected to report for Q3 2023 Neogen Corporation (NEOG) is expected to report $0.14 for Q1 2024 E2open Parent Holdings Inc.Class A (ETWO) is expected to report $0.04 for Q2 2024 TSR Inc. (TSRI) is expected to report for Q1 2024 Solitron...

Cytodyn Inc (CYDY) is expected to report for quarter end 2023-08-31

Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24 th , 2023, at 1 PM PT / 4 PM ET VANCOUVER, Washington, July 11, 2023 (GLOBE NEWSWIRE) -- Cyt...

2023-05-24 17:16:00 ET Cyrus Arman, CytoDyn ( OTCQB:CYDY ) president, has taken a medical leave of absence. CFO Antonio Migliarese will assume Arman's responsibilities while he is out. Migliarese will be assisted by interim CMO Melissa Palmer and Salah Kivlighn, ...

Antonio Migliarese assumes interim President role Dr. Melissa Palmer appointed interim Chief Medical Officer Dr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington, May 24, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or th...

VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Ar...

2023-03-28 10:52:34 ET Summary Former CytoDyn CEO Pourhassan's indictment is now public. Company is moving on with an entirely different management team. CytoDyn shares and its finances are both in the dumps. CytoDyn's future holds little promise for current shareholders. ...

Summary CYDY changed its CEO and made other major changes to the company. The company is trying to move away from initial indications to others that haven't failed yet. However, the entire leronlimab program is now in question. A few months ago, I wrote a bearish article...

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pac...

Nader Pourhassan, the former CEO of embattled biotech CytoDyn ( OTCQB:CYDY ), has been indicted by a federal court grand jury and accused of conspiracy to defraud investors in regards to the company's HIV candidate leronlimab. The stock is down ~12% in Tuesday afternoon ...